Oxford Astrazeneca
- All
- News
- Videos
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
- Thursday May 16, 2024
- World News | Indo-Asian News Service
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
- www.ndtv.com
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
- Monday May 6, 2024
- India News | Reported by Ashish Bhargava
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
- www.ndtv.com
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
- Tuesday April 30, 2024
- India News | Indo-Asian News Service
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
- www.ndtv.com
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
- Monday February 6, 2023
- India News | Press Trust of India
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
- www.ndtv.com
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
- Thursday December 23, 2021
- India News | Asian News International
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
- www.ndtv.com
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
- Thursday December 23, 2021
- World News | Reuters
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
- www.ndtv.com
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
- Monday December 6, 2021
- World News | Press Trust of India
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
- www.ndtv.com
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
- Tuesday October 26, 2021
- World News | Press Trust of India
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
- www.ndtv.com
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
- Friday August 27, 2021
- World News | Press Trust of India
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
- www.ndtv.com
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
- Wednesday August 25, 2021
- World News | Reuters
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
- www.ndtv.com
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
- Thursday August 19, 2021
- World News | Agence France-Presse
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
- www.ndtv.com
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
- Thursday August 12, 2021
- World News | Press Trust of India
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
- www.ndtv.com
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
- Thursday August 12, 2021
- World News | Grace Gitau, Bloomberg
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
- www.ndtv.com
-
No Ban On Covishield, Request Must For Approval Process: EU Envoy To India
- Tuesday June 29, 2021
- India News | Asian News International
European Union (EU) Ambassador to India Ugo Astuto has clarified there is no ban in the EU on the Covishield vaccine produced by the Serum Institute of India (SII) and developed by AstraZeneca and Oxford University.
- www.ndtv.com
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
- Tuesday June 29, 2021
- World News | Katharine Gemmell, Bloomberg
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
- www.ndtv.com
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
- Thursday May 16, 2024
- World News | Indo-Asian News Service
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
- www.ndtv.com
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
- Monday May 6, 2024
- India News | Reported by Ashish Bhargava
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
- www.ndtv.com
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
- Tuesday April 30, 2024
- India News | Indo-Asian News Service
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
- www.ndtv.com
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
- Monday February 6, 2023
- India News | Press Trust of India
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
- www.ndtv.com
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
- Thursday December 23, 2021
- India News | Asian News International
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
- www.ndtv.com
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
- Thursday December 23, 2021
- World News | Reuters
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
- www.ndtv.com
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
- Monday December 6, 2021
- World News | Press Trust of India
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
- www.ndtv.com
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
- Tuesday October 26, 2021
- World News | Press Trust of India
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
- www.ndtv.com
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
- Friday August 27, 2021
- World News | Press Trust of India
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
- www.ndtv.com
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
- Wednesday August 25, 2021
- World News | Reuters
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
- www.ndtv.com
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
- Thursday August 19, 2021
- World News | Agence France-Presse
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
- www.ndtv.com
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
- Thursday August 12, 2021
- World News | Press Trust of India
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
- www.ndtv.com
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
- Thursday August 12, 2021
- World News | Grace Gitau, Bloomberg
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
- www.ndtv.com
-
No Ban On Covishield, Request Must For Approval Process: EU Envoy To India
- Tuesday June 29, 2021
- India News | Asian News International
European Union (EU) Ambassador to India Ugo Astuto has clarified there is no ban in the EU on the Covishield vaccine produced by the Serum Institute of India (SII) and developed by AstraZeneca and Oxford University.
- www.ndtv.com
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
- Tuesday June 29, 2021
- World News | Katharine Gemmell, Bloomberg
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
- www.ndtv.com